What Is Dihexa? Complete Guide to PNB-0408

Origins and Discovery

Dihexa is a synthetic peptide compound designated as PNB-0408, developed at Washington State University by a team of neuroscience researchers led by Dr. Joseph Harding and Dr. John Wright in the university's neuroscience laboratory. The compound emerged from decades of focused research into peptide-based therapies for neurodegenerative diseases, particularly Alzheimer's disease and age-related cognitive decline.

The discovery of Dihexa represents a significant departure from traditional approaches to cognitive enhancement, which have historically relied on modulating neurotransmitter systems. Instead, Dihexa targets a fundamentally different pathway — the hepatocyte growth factor (HGF) and its receptor, c-Met — to promote neural growth, connectivity, and repair at the cellular level.

The Washington State University research program, funded through multiple grants and institutional support, has produced a growing body of preclinical evidence suggesting that Dihexa may offer neuroprotective and neuroenhancing properties beyond what conventional nootropics can achieve. The peptide's development was motivated by the urgent need for disease-modifying treatments in neurodegenerative diseases, where current pharmaceutical approaches provide only symptomatic relief.

Chemical Structure and Formula

Dihexa is chemically identified as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, a synthetic modification of angiotensin IV. The compound's molecular formula is C₂₇H₄₄N₄O₅, with a molar mass of 504.672 g/mol. This specific chemical structure is proprietary to the research program and represents an optimisation of the parent angiotensin IV molecule for improved bioavailability and target engagement.

The hexanoic acid substitution (the "di" in Dihexa refers to two hexanoic acid chains) on either end of the core peptide scaffold significantly enhances the compound's ability to cross the blood-brain barrier and resist enzymatic degradation in the body. This modification is crucial to the compound's efficacy, as it allows the peptide to reach brain tissue in meaningful concentrations after systemic administration.

The precise three-dimensional structure of Dihexa enables specific binding to the HGF/c-Met receptor complex with high affinity, a property that underlies its purported neuroenhancing effects. The peptide exists in equilibrium between multiple conformational states, and the physiologically active form is stabilised by the hexanoic acid modifications and the careful positioning of the core amino acids.

Angiotensin IV Derivative Explained

Dihexa is derived from angiotensin IV, a naturally occurring peptide hormone produced when the body metabolises angiotensin II. Angiotensin IV is part of the renin-angiotensin system, a complex regulatory pathway that controls blood pressure, fluid balance, and vascular function. However, angiotensin IV also has significant effects on brain function, and several studies in the 1990s and 2000s demonstrated that this peptide enhances memory and cognitive performance in animal models.

Researchers at Washington State University recognised that angiotensin IV's cognitive-enhancing properties were mediated through a receptor different from the classical angiotensin II receptors (AT1 and AT2). They identified this receptor as the HGF/c-Met pathway, which is more commonly associated with tissue growth and regeneration outside the nervous system. This discovery was novel and opened an entirely new avenue for neurocognitive research.

Dihexa is a structural analogue of angiotensin IV designed to be a more potent and selective activator of the HGF/c-Met pathway in the brain, while minimising effects on the cardiovascular system. By chemically modifying the parent angiotensin IV structure with hexanoic acid chains, researchers created a compound that retains the cognitive-enhancing properties of the original while offering superior blood-brain barrier penetration and metabolic stability.

The key insight here is that Dihexa represents a deliberate shift away from angiotensin IV's cardiovascular function toward its neuroprotective and neuroenhancing mechanisms. The compound is not, and should not be thought of as, a modified blood pressure drug; it is a peptide engineered specifically to interact with neural growth signalling pathways.

Why Dihexa Was Created

Dihexa was created in response to a fundamental problem in neuroscience and neurology: the lack of effective disease-modifying treatments for Alzheimer's disease and other forms of neurodegeneration. Current pharmaceutical approaches, whether cholinesterase inhibitors or NMDA antagonists, provide only temporary symptomatic improvement and do not address the underlying pathology of neuronal loss and synaptic dysfunction.

The Washington State University research team hypothesised that promoting the intrinsic regenerative capacity of the brain through activation of the HGF/c-Met pathway might offer a fundamentally different therapeutic approach. Rather than simply enhancing neurotransmitter availability, as traditional nootropics do, Dihexa was designed to stimulate the growth and strengthening of neural connections, the formation of new synapses, and the stabilisation of existing neural circuits.

This approach has deep evolutionary roots. The HGF/c-Met pathway is one of the most ancient signalling systems in biology, regulating tissue growth and repair across diverse organ systems. In the brain, this pathway is active during development and is capable of being reactivated in adulthood under the right stimulation. The researchers reasoned that pharmacologically activating this pathway could promote neuroplasticity and neural resilience even in aged or damaged brains.

The development of Dihexa was also motivated by the success of neurotrophic factor research, which demonstrated that growth factors like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) have profound protective and regenerative effects in the nervous system. However, these protein-based factors have severe limitations for therapeutic use: they cannot cross the blood-brain barrier, they are rapidly degraded, and they are immunogenic. Dihexa offers a small-molecule peptide alternative with theoretical advantages in terms of stability and bioavailability.

What Makes Dihexa Different from Other Nootropics

The nootropics landscape is dominated by compounds that modulate neurotransmitter systems: stimulants that increase dopamine and noradrenaline, GABAergics that enhance inhibitory signalling, or cholinergics that boost acetylcholine availability. These compounds work by adjusting the concentration or activity of chemical messengers that already exist in the brain. They are essentially "volume dials" on existing neural circuits.

Dihexa operates on a fundamentally different principle. Rather than modulating neurotransmitter levels, it activates the HGF/c-Met signalling pathway, which promotes the structural remodelling of neural circuits at the synaptic level. This includes the formation of new synaptic connections (synaptogenesis), the growth and enlargement of dendritic spines, the stabilisation of synaptic strength through long-term potentiation (LTP), and even the upregulation of gene expression programmes that support neural plasticity and resilience.

A critical distinction: traditional nootropics produce acute, reversible effects that depend on the continued presence of the compound. When you stop taking a dopaminergic stimulant, dopamine levels return to baseline. Dihexa's effects, by contrast, are thought to be more durable because they involve lasting changes to neural structure and gene expression. Preclinical evidence suggests that the neuroplastic changes induced by Dihexa can persist long after the compound has been metabolised and eliminated from the body.

Another key difference is the breadth of application. Most traditional nootropics are developed for a specific indication — stimulation, anxiety reduction, sleep improvement — and their effects are relatively narrow. Dihexa, working through a fundamental neuroplasticity pathway, has shown promise across a diverse range of preclinical models: Alzheimer's disease, traumatic brain injury, age-related cognitive decline, and normal memory enhancement in healthy animals. This breadth of activity reflects the central role of the HGF/c-Met pathway in neural function.

Finally, Dihexa operates through a mechanism that is fundamentally different from any other pharmaceutical agent in clinical use or advanced development. There are no established competitors because the HGF/c-Met pathway as a target for cognitive enhancement is a relatively recent discovery. This represents both an opportunity (potentially novel clinical benefits) and a limitation (limited human data, uncertain long-term effects).

Blood-Brain Barrier Penetration and Oral Bioavailability

One of the most significant engineering challenges in peptide therapeutics is crossing the blood-brain barrier (BBB), a highly selective membrane that prevents most large molecules from entering the central nervous system. The BBB is essential for protecting the brain from pathogens and toxins, but it also excludes many potentially therapeutic compounds.

Most peptides, including the parent angiotensin IV, are hydrophilic (water-soluble) and therefore cannot cross the BBB efficiently. This is where the hexanoic acid modifications on Dihexa become critical. These lipophilic (fat-soluble) chains increase the overall lipophilicity of the molecule, enhancing its ability to cross the BBB via diffusion or carrier-mediated transport mechanisms. Preclinical studies confirm that Dihexa effectively penetrates brain tissue in rodent models.

Oral bioavailability — the fraction of an orally administered dose that reaches the systemic circulation in active form — is another major hurdle for peptides. Most peptides are rapidly degraded by proteases in the gastrointestinal tract and liver. Dihexa's reported oral bioavailability is approximately 38%, which is relatively high for a peptide compound. This is achievable because the hexanoic acid modifications confer resistance to enzymatic degradation.

The BBB penetration and oral bioavailability of Dihexa are what enable its putative therapeutic potential. Without these pharmacokinetic properties, the compound would accumulate in peripheral tissues and fail to reach brain receptors. The engineering of these properties was a central achievement of the Washington State University research program and remains a key advantage over structurally unmodified angiotensin IV.

Understanding the "10 Million Times More Potent" Claim

One frequently cited claim about Dihexa is that it is "10 million times more potent than BDNF." This claim requires careful contextualisation, as it is a common source of misunderstanding and unrealistic expectations.

To understand this claim, it is essential to distinguish between different types of potency measurements. In neuroscience, potency is typically expressed as EC50 (effective concentration at 50% of maximal response). When researchers measure synaptogenesis in cultured neurons and calculate the EC50 for Dihexa versus BDNF, they find that Dihexa achieves the same dendritic spine formation at a substantially lower concentration than BDNF.

However, this comparison has several important caveats. First, Dihexa and BDNF activate different receptors through different signalling cascades. Dihexa works through HGF/c-Met, while BDNF works through TrkB and p75. These are not equivalent systems, and comparing their potencies is somewhat like comparing the efficiency of two different machines doing different jobs. The potency difference tells us that Dihexa is more efficient at activating c-Met-mediated synaptogenesis, not that it is universally more powerful than BDNF.

Second, the "10 million times" measurement is specific to a particular assay under particular conditions. In different experimental contexts or in vivo, the relative potency might be considerably less impressive. Potency measured in a cell culture dish does not always translate to efficacy in living organisms.

Third, and most importantly, this comparison reflects molar potency — the concentration needed to achieve an effect — not biological impact or clinical relevance. Dihexa might require picomolar concentrations in an assay while BDNF requires nanomolar concentrations, giving a millionfold difference in concentration, but this does not mean Dihexa's clinical effects are a million times stronger. That would require assumptions about human physiology and in vivo behaviour that are not supported by the data.

The "10 million times" claim is scientifically accurate in its specific context but is misleading if interpreted as a general statement of superiority. It should be read as: "In a specific synaptogenesis assay, Dihexa achieves a given level of dendritic spine formation at a substantially lower molar concentration than BDNF," not as "Dihexa is 10 million times better than BDNF."

Why All Evidence Is Preclinical: The Critical Caveat

All published evidence for Dihexa's effects comes from preclinical studies: laboratory experiments in cultured cells and animal models (primarily rodents). As of 2026, there are no published results from completed human clinical trials of Dihexa itself. This is a fundamental limitation that must inform any discussion of the compound.

Preclinical evidence is essential for understanding a compound's basic pharmacology, mechanism of action, and preliminary efficacy signals. However, preclinical models are not human beings. Rodent brains are not human brains; cultured neurons are not intact neural circuits; and laboratory conditions are not the complexity of living organisms.

Many compounds show remarkable effects in preclinical studies but fail in human trials due to:

• Pharmacokinetic differences (the compound is metabolised differently in humans)
• Target engagement issues (the drug reaches the intended receptor at lower levels than in animal models)
• Off-target effects (the compound interacts with unintended receptors in humans)
• Species-specific toxicity (humans respond differently to the compound than the test species)
• Insufficient efficacy in the disease state (the effect size is too small to be clinically meaningful)

The absence of human clinical trial data means that Dihexa's actual effects in humans remain unknown. The preclinical evidence is compelling and suggestive of potential benefits, but it cannot be taken as proof that those benefits will manifest in people. Any use of Dihexa currently would be experimental and would carry unknowns risks and uncertain benefits.

Furthermore, long-term safety data is limited even in preclinical models. Chronic administration of compounds that activate neural growth pathways could theoretically lead to unintended neural overgrowth, aberrant connectivity, or other adverse effects that would only manifest with extended exposure. Whether such risks are real or hypothetical cannot be determined without long-term human studies.

Key Terminology Glossary

Angiotensin IV

A naturally occurring peptide hormone derived from the renin-angiotensin system that has been found to enhance memory and cognitive function in animal models. The parent compound from which Dihexa was derived.

Blood-Brain Barrier (BBB)

A highly selective membrane that controls what substances can enter the central nervous system from the blood. Most large molecules cannot cross the BBB, which is why Dihexa's BBB penetration is a significant advantage.

c-Met (Hepatocyte Growth Factor Receptor)

A receptor protein on the surface of cells that binds hepatocyte growth factor (HGF) and initiates cellular signalling. Activation of c-Met promotes cell growth, survival, and tissue regeneration. Dihexa activates this receptor in neurons.

Dendritic Spine

A small protrusion on neuronal dendrites that form the post-synaptic side of synapses. The size and number of dendritic spines correlate with learning and memory capacity. Dihexa increases dendritic spine density and size in preclinical models.

Hepatocyte Growth Factor (HGF)

A protein growth factor that was originally identified in liver tissue but is now recognised as playing crucial roles in neural development, repair, and regeneration. HGF is produced by glial cells in the brain and signals through the c-Met receptor.

Long-Term Potentiation (LTP)

A persistent strengthening of synaptic transmission that occurs when two neurons fire together repeatedly. LTP is a fundamental mechanism of learning and memory. Dihexa enhances LTP in preclinical studies.

Neuroprotection

The preservation of neuronal structure and function, particularly in the context of injury, disease, or neurodegeneration. Compounds that prevent neuronal death or promote neuronal survival are called neuroprotective.

Neuroplasticity

The ability of the brain to structurally and functionally adapt in response to experience, injury, or learning. Neuroplasticity underlies learning and memory and declines with age. Dihexa is thought to enhance neuroplasticity through HGF/c-Met signalling.

Preclinical

Research conducted in laboratory settings (cell cultures, animal models) before human clinical trials. Preclinical evidence establishes proof of concept but cannot definitively predict human efficacy or safety.

Synaptogenesis

The formation of new synaptic connections between neurons. Enhanced synaptogenesis is thought to underlie learning, memory, and cognitive enhancement. Dihexa promotes synaptogenesis in preclinical models through HGF/c-Met signalling.

Learn More

For a deeper understanding of how Dihexa works at the molecular level, see our detailed article on How Dihexa Works: The HGF/c-Met Pathway.

For information on the potential benefits of Dihexa based on preclinical evidence, read Potential Benefits of Dihexa: Cognitive Enhancement and Neuroprotection.

For a review of the research underpinning these claims, see Research and Studies.

For practical information about dosing and administration, visit our Dosage and Administration page.